Regulatory
FDA Expands Camzyos to Teenagers With Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb’s heart drug becomes the first of its class approved for adolescents with the inherited condition, a leading cause of sudden cardiac death in young people.